Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SULF2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SULF2 Recombinant Protein (ECD-Fc / His Tag) High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View SULF2 Products |
| Gene Delivery | SULF2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View SULF2 Products |
| Benchmark Ab | Anti-SULF2 Recombinant Antibody Recombinant positive control for binding and functional inhibition assays. |
View SULF2 Products |
| Validator | SULF2 siRNA Set Target-specific knockdown verification in target-expressing cancer cell lines. |
View SULF2 Products |
| Related Target A | SULF1 Highly homologous sulfatase. Essential for counter-screening to ensure SULF2-specific drug candidate selectivity. |
View SULF1 Products |
| Related Target B | GPC3 Glypican-3, a heparan sulfate proteoglycan coreceptor. Cooperates with SULF2 in hepatocellular carcinoma (HCC) signaling. |
View GPC3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SULF1 vs SULF2 Subfamily Selectivity | SULF1 and SULF2 recombinant proteins strictly verified by mass spectrometry and sequence analysis for precise counter-screening. |
| Conformation & Glycosylation Dependency | HEK293 mammalian expression host ensures native post-translational modifications and correct folding of the large hydrophilic domain. |
| Lack of Validated Positive Controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| Off-Target & False Positive Verification | Sequence-specific siRNA sets included for target validation and phenotypic knockdown assays. |
Live SULF2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SULF2 therapeutics is intensifying, with major players shifting focus from traditional small-molecule sulfatase inhibitors to highly selective monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). Because SULF2 acts as an extracellular enzyme that remodels the tumor microenvironment by liberating heparin-bound growth factors (such as Wnt, FGF, and VEGF), targeting it offers a dual therapeutic benefit: direct inhibition of tumor growth and disruption of the supportive stromal niche. As first-generation therapies reach preclinical milestones, the next wave of R&D is targeting selective SULF2 inhibition without cross-reacting with the tumor-suppressive homolog SULF1.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Oncology-focused Biotechs | Hepatocellular Carcinoma (HCC), NSCLC | High-affinity binding assays (Need HEK293-expressed SULF2 ECD) |
| Antibody-Drug Conjugate (ADC) | Targeted Therapeutics Developers | Triple-Negative Breast Cancer (TNBC), Pancreatic Cancer | Internalization assays and cell-surface binding (Need Lentivirus for stable cell lines) |
| Small Molecule Inhibitor | Enzyme Inhibitor Specialists | Idiopathic Pulmonary Fibrosis (IPF), Solid Tumors | Enzymatic activity and selectivity panels (Need SULF2 vs SULF1 recombinant proteins) |